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Background: Radiological markers of treatment response and prognostication in malignant pleural mesothelioma have limitations
due to the morphology of the disease. Serum or pleural fluid biomarkers that could act as an adjunct to radiological assessment
would be of significant value. The aim of this review was to collate and summarise the literature relating to this topic.
Methods: A systematic review was performed on the databases Pubmed and EMBASE to identify relevant studies. Two
independent researchers read the abstracts and used the Quality in Prognostic Studies tool to assess the quality of the evidence.
Results: Forty-five studies were identified from the current literature. Twenty studies investigated the role of serum soluble
mesothelin with majority suggesting that it has variable utility as a baseline test but when measured serially correlates with
treatment response and prognosis. Several studies demonstrated that serum osteopontin correlated with survival at baseline.
Other biomarkers have shown prognostic utility in individual studies but are yet to be reproduced in large cohort studies.
Conclusions: From the available literature no serum or pleural fluid biomarker was identified that could be recommended
currently for routine clinical practice. However, a falling serum soluble mesothelin might correlate with treatment response and
improved survival.
Malignant pleural mesothelioma (MPM) is a rapidly progressive
and invariably fatal malignancy. Mean survival is 9–14 months
from diagnosis (Chapman et al, 2008). First-line palliative
chemotherapy with pemetrexed and a platinum-based agent
(Cisplatin or Carboplatin) has been the standard of care for over
a decade (Vogelzang et al, 2003). However, following encouraging
results from the MAPS trial, many guidelines are now advocating
the addition of bevacizumab to this regimen (Zalcman et al, 2016).
Despite this, chemotherapy has only a modest impact on survival
of around 2–3 months with a possible small improvement in
symptomatology (Arnold et al, 2015). Response to chemotherapy
differs greatly between patients with a partial response rate of
30–40% (Vogelzang et al, 2003). Clinical trials and clinicians use
radiological markers to assess treatment response and progression-
free survival (PFS). The current best practice is serial thoracic
computerised tomography (CT) scans reported using the modified
RECIST criteria, a technique which only partially allows for the fact
that MPM usually grows as a pleural rind as opposed to a spherical
mass. Other challenges, such as the presence of pleural fluid (pf)
and benign asbestos-related plaques, make radiological assessment
of MPM difficult (Armato et al, 2006).
A blood or pf biomarker that could act as an adjunct to
radiological assessment by giving prognostic information as well as
reflecting response to treatment would be of considerable use to
clinicians. The majority of literature on biomarkers in MPM
focuses on their utility as a screening or diagnostic test. Most
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researched is soluble mesothelin (SM)-related peptide often called
SM. Soluble mesothelin is the circulating form of a 40 kDa
membrane-bound glycoprotein and is highly expressed by
mesothelial cells in MPM and some other cancers (Robinson
et al, 2003). Soluble mesothelin levels are much higher in
epithelioid MPM compared with other histological subtypes, and
in larger tumours. However, its diagnostic ability in both serum
and pf is limited by an inability to exclude MPM with a negative
result. Another biomarker is megakaryocyte potentiating factor
(MPF), also called N-ERC/mesothelin as it is formed
from the same precursor protein as SM (Hollevoet et al, 2010).
Osteopontin (OPN) is a glycoprotein that mediates cell-matrix
interactions and has been shown to infer a poor phenotype when
raised in other malignancies, including breast, lung and colon (Pass
et al, 2005; Shojaei et al, 2012). Finally, fibulin-3 is an extracellular
glycoprotein, which has shown promise in the diagnosis of MPM
(Pass et al, 2012), but information on its role in prognostication is
limited. We performed a systematic review of studies that had
assessed the role of biomarkers in providing prognostic and
treatment response information for MPM in an attempt to guide
clinicians as to the strength of evidence for use in current practice.
MATERIALS AND METHODS
Search strategy. The databases PubMed (Medline) and EMBASE
were interrogated for papers related to our study question. The 30
June 2016 was used as a cut-off with no early limit date applied.
The search was limited to English language papers using the search
terms shown in Supplementary Table 1. The search terms were
designed to limit the search to papers that provided information on
prognostication and disease monitoring and have been used in
previous such studies (Altman, 2001; Dretzke et al, 2014). Articles
were also identified using the ‘related articles’ function of PubMed
and the references of the selected papers were assessed for other
relevant papers. Two reviewers (DA and FH) screened the abstracts
for study eligibility; any disagreements were resolved by mutual
consensus.
Study inclusion criteria
 Involved the measurement of a serum or pf biomarker in
patients with proven MPM.
 Treatment response or survival data collected and correlated
with biomarkers.
Study exclusion criteria
 Reported only biomarkers from tumour immunohistochemistry.
 Results duplicated from another selected study.
 Involved less than 10 patients with MPM.
 Conference abstract or letter.
Quality assessment and data extraction. Once the full set of articles
were extracted, two reviewers (DA and FH) independently applied the
quality in prognostic studies (QUIPS) tool to assess the quality of
selected studies (Hayden et al, 2013). The QUIPS score of each paper
has been reported in Supplementary Table 2. In addition, routine data
were extracted from the studies including author, publication year,
study type (prospective or retrospective), patient number, histological
subtype, patient treatment and biomarkers studied.
Data extraction was dependant on the findings reported by
the individual studies. Correlation of biomarkers with survival is
reported using univariate or multivariate Cox-regression analysis
unless otherwise stated. Any survival time comparisons are reported
using hazard ratios (HR) with 95% confidence intervals (CI).
RESULTS
The search strategy generated 1325 abstracts from the Pubmed and
EMBASE databases. After screening all the abstracts, 68 were read
in full by the independent reviewers. A further 23 were excluded as
they did not meet the review criterion (see Figure 1). Therefore,
45 studies were included in the final review. Because of consider-
able heterogeneity between studies in areas such as histological
subtype, biomarker testing and patient therapy, no attempt to
combine or meta-analyse the data was made. The selected studies
are shown in Table 1 and summarised by biomarker below.
Soluble mesothelin (SM). Serum/plasma SM was the most
studied biomarker with 20 studies (18 prospective, 2 retrospective),
a total of 1578 patients, investigating its role as a marker of
prognostication or treatment response (Robinson et al, 2003;
Cristaudo et al, 2007; Grigoriu et al, 2007; Pass et al, 2008;
Schneider et al, 2008; Grigoriu et al, 2009; Wheatley-Price et al,
2010; Creaney et al, 2011; Hollevoet et al, 2011; Yamada et al, 2011;
Franko et al, 2012; Hollevoet et al, 2012; Kao et al, 2012; Creaney
et al, 2013; Nowak et al, 2013; Creaney et al, 2014; Hassan et al,
2014; Linch et al, 2014; Hooper et al, 2015; Pass et al, 2016). Early
studies were primarily aimed at SM’s ability to diagnose MPM
from other malignant or benign lung pathologies with its role as a
prognostic indicator a secondary outcome. The earliest study of SM
in prognosis, correlated tumour size on CT with baseline SM,
finding that levels were significantly higher in larger tumours
(Po0.01) and those of epithelioid histology (Po0.01), but there
was no correlation with overall survival (OS) (Robinson et al,
2003). Studies by Cristaudo et al (2007) and Grigoriu et al (2007)
using the Mesomark ELISA found that higher baseline SM was
correlated with worse OS using cut-offs of 1 nmol l 1 (HR: 1.6, CI:
1.1–2.4) and 3.5 nmol l 1 (HR: 2.8, CI: 1.4–5.6), respectively. Both
papers combined patients who were treated with surgery,
chemotherapy or best supportive care (BSC). The cut-offs used
were selected from diagnostic studies or maximisation of HR
models. In a study of 91 MPM patients who received a variety of
chemotherapeutic regimens, there was a significant difference in
OS between low (o3.5 nmol l 1) and high baseline SM levels of
17.1 months vs 8.4 months, respectively (Schneider et al, 2008).
This relationship was statistically significant at multivariate
analysis (HR: 1.9, CI: 1.1–3.5, P¼ 0.025) but lost statistical
significance when applied to epithelioid histology alone. Two
studies from Creaney et al (2013, 2014) involving 96 and 82
patients, respectively, found no correlation between OS and
baseline serum SM.
An earlier prospective study from the same author tested the
role of serum SM as a proxy for treatment response when
measured serially (Creaney et al, 2011). They recruited 95 patients
with MPM and tested serum SM at baseline, every 3 months and
before every chemotherapy cycle, alongside thoracic CT scanning.
Baseline SM was not correlated with OS at multivariate analysis
when radiological markers of FDG-PET were included. In the
chemotherapy group (n¼ 61), there was a correlation between
response on modified RECIST CT scans and changes in SM
(P¼ 0.023). They classified a rise or fall in SM as a change of
greater than 25%, otherwise classifying as stable SM. In patients
with partial response on CT (17 out of 55) none had a rise in SM
with 5 stable levels and 12 falling. In 28 patients who had a repeat
FDG-PET as part of follow-up, there was a correlation between
percentage change in SM levels and percentage change in tumour
TGV and volume (Po0.01). They also found a correlation between
change in SM levels and OS with both the stable and rising groups
having increased risk compared with the falling group, with HR
of 2.0 (CI: 1.1–3.1) and 23.0 (CI: 7.5–70.9), respectively. In the
small number of patients in this study who had an extrapleural
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pneumonectomy (n¼ 6), there was a mean 54% decrease in SM
level pre to post surgery. There was no further testing of SM on
these surgical patients to assess its role in predicting recurrent
disease. Wheatley-Price et al (2010) published a similar study of 41
patients with non-sarcomatoid mesothelioma (39 pleural and 2
peritoneal) of whom 92% had an elevated baseline serum SM.
Changes in SM or OPN were correlated with radiological reports
(using descriptive reporting, RECIST and mod RECIST) during
treatment. There was a significant association between relative and
absolute change in SM and radiology reporting (all methods),
the former having consistently better predictive value. Despite
small numbers (n¼ 13), the same effect was seen in the BSC
group with an average rise of SM by 26 and 60% for stable and
progressed disease on mod RECIST criteria (P¼ 0.004). In total,
this review identified eight studies that assessed the utility of
serial serum SM testing in MPM. All found a correlation between
falling SM levels and radiological response and/or improved OS
(see Table 2).
Five studies (four prospective, one retrospective), with a total of
371 patients, investigated pf SM’s ability to prognosticate from
baseline (Creaney et al, 2007; Grigoriu et al, 2007; Yamada et al,
2011; Creaney et al, 2013, 2014). One study by Yamada et al (2011)
found patients (n¼ 45) with higher pf SM levels survived
significantly longer (dichotomy at 10 nM) at univariate but not
Abstracts identified from Pubmed and
EMBASE database search strategy
(n=1322)
Total abstracts screened
(n=1325)
Full-text articles accessed
(n=68)
Studies relevant to study question
and fulfilling-specified criteria
(n=45)
Full-text articles excluded;
Relating to tumour biomarkers
only (n=5)
Duplicate results (n=1)
No biomarker assessed (n=11)
Small study (<10 patients)
(n=2)
No survival or treatment
response analysis (n=2)
Conference abstract (n=2)
Biomarkers included in the 45
selected articles;
Mesothelin (21)
- Blood (20)
- Blood (5)
- Blood (6)
- Blood (4)
- Blood (5)
- Blood (11)
- Blood (6)
Osteopontin (6)
Fibulin-3 (6)
Hyaluronic acid (5)
Other biomarkers (12)
VEGF (6)
- PF (5)
- PF (2)
- PF (3)
- PF (3)
- PF (2)
- PF (4)
MPF (5)
Total abstracts excluded
(n=1257)
Abstracts identified from references
of full-text articles
(n=3)
Figure 1. PRISMA flowchart.
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Table 1. Full table of selected studies
Author (year) Study type Biomarker No. pts Histology Treatment
Pass et al (2016) Prospective SM (p)
Fibulin-3 (p)
OPN (p)
194 E – 135
NE – 59
Surg – 100
C – 141
RTX – 68
Kirschner et al (2015) Retrospective Fibulin-3 (p)
Fibulin-3 (pf)
84
30
E – 88
S – 7
B – 17
D – 2
N/D
Hooper et al (2015) Prospective SM (s)
Fibulin-3 (s)
73 E – 50
S – 19
B – 4
C – 58
BSC – 15
Kaya et al (2015) Prospective Fibulin-3 (s) 43 E – 30
NE – 13
C – 15
Surg – 7
BSC – 21
Fujimoto et al (2014) Retrospective CD26 (s)
CD26 (pf)
80 E – 53
S – 9
B – 18
N/D
Raphael et al (2015) Prospective CTC (s) 27 E – 22
NE – 5
N/D
Linch et al (2014) Prospective SM (s) 53 E – 46
S – 1
B – 5
U – 1
C – 30
BSC – 23
Mundt et al (2014a) Prospective Syndecan 1 (s)
OPN (s)
Syndecan 1 (pf)
OPN (pf)
91
89
E – 62
S – 10
B – 13
Un – 95
N/D
Mundt et al (2014b) Prespective Novel proteomes (s) 37 N/D N/D
Hassan et al (2014) Prospective SM (s)
MPF (s)
Ca125 (s)
24 N/D C/Im – 24
Creaney et al (2014) Prospective Fibulin-3 (p)
SM (p)
Fibulin-3 (pf)
SM (pf)
82 E – 32
S – 8
B – 13
U – 29
C – 37
Surg – 4
BSC – 37
U – 4
Ghanim et al (2014) Retrospective Fibrinogen (p) 176 E – 146
S – 12
B – 18
C – 78
Surg – 54
BSC – 44
Mori et al (2013) Prospective MPF (s) 26 E – 21
S – 4
B – 1
C – 26
Creaney et al (2013) Retrospective SM (s)
HA (s)
SM (pf)
HA (pf)
96 E – 53
S – 2
B – 9
U – 32
N/D
Tabata et al (2013) Prospective HMGB 1 (s) 61 E – 43
S – 8
B – 6
D – 3
A – 1
N/D
Nowak et al (2013) Prospective SM (s)
VEGF isoforms (s)
Interleukin-8 (s)
S-Kit (s)
53 E – 39
S – 1
B – 10
Un – 3
Bio – 53
(second line)
Franko et al (2012) Prospective SM (s) 78 E – 64
S – 7
B – 7
C – 64
Surg – 10
BSC – 4
Kao et al (2012) Prospective SM (s)
CRP (s)
IL-6 (s)
sIL-6r (s)
VEGF (s)
63 E – 28
S – 4
B – 30
C – 63
Pass et al (2012) Prospective Fibulin-3 (p)
Fibulin-3 (pf)
92
74
N/D N/D
Kindler et al (2012) Prospective VEGF (p) 108 E – 76
NE – 32
C/Bio – 53
C – 55
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Table 1. ( Continued )
Author (year) Study type Biomarker No. pts Histology Treatment
Ghanim et al (2012) Retrospective CRP (s) 115 E – 80
S – 27
U – 8
Cþ /RTX – 64
Surg – 51
Hollevoet et al (2012) Prospective SM (s)
MPF (s)
106 E – 91
S – 7
B – 8
C – 78
Surg – 19
BSC – 9
Yamada et al (2011) Prospective SM (pf) 45 E – 37
S – 5
B – 3
N/D
Hirayama et al (2011) Prospective VEGF (pf) 46 E – 34
S – 10
B – 2
N/D
Hollevoet et al (2011) Prospective SM (s)
MPF (s)
OPN (p)
62 E – 59
S – 1
B – 2
C – 48
Surg – 14
Yasumitsu et al (2010) Prospective VEGF (s) 51 E – 36
S – 6
B – 6
D – 3
N/D
Creaney et al (2011) Prospective SM (s) 95 E – 68
S – 9
B – 18
C – 61
Surg – 7
RTX – 2
BSC – 25
Grigoriu et al (2009) Retrospective SM (s) 40 E – 35
S – 3
B – 2
Im – 16
C – 20
BSC – 4
Wheatley-Price et al
(2010)
Prospective SM (p)
OPN (p)
41 E – 41 C – 21
Surg – 7
BSC – 13
Schneider et al (2008) Prospective SM (s) 129 E – 81
S – 14
B – 17
U – 17
C – 68
Surg – 41
RTX – 4
BSC – 9
Un – 7
Pass et al (2008) Prospective SM (s) 90 E – 58
S – 3
B – 29
Surg – 90
Tajima et al (2008) Prospective MPF (s)
OPN (p)
14 E – 11
S – 2
B – 1
C – 14
Grigoriu et al (2007) Prospective SM (s)
OPN (s & p)
SM (pf)
OPN (pf)
96 E – 73
S – 10
B – 13
C – 70
Surg – 10
BSC – 16
Cristaudo et al (2007) Prospective SM (s) 107 E – 72
S – 10
B – 7
D – 3
U – 15
N/D
Creaney et al (2007) Prospective SM (s)
SM (pf)
52 E – 15
S – 9
B – 5
U – 23
N/D
Filiberti et al (2005) Prospective PDGF-AB (s) 93 N/D N/D
Robinson et al (2003) Prospective SM (s) 44 E – 25
S – 4
U – 15
N/D
Hedman et al (2003) Retrospective HA (s)
Ca125 (s)
TPA (s)
11 N/D N/D
Strizzi et al (2001) Retrospective VEGF (s)
VEGF (pf)
12 E – 8
S – 1
B – 3
N/D
Thylen et al (2001) Retrospective HA (pf) 100 E – 67
NE – 33
C – 56
BSC – 44
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multivariate analysis. This finding was not replicated in the other
larger studies, which found no relationship between pf SM and OS.
Megakaryocyte potentiating factor (MPF) or N-ERC/mesothelin.
All five studies (five prospective), with a total of 232 patients,
involving serum MPF were published after 2008 (Tajima et al,
2008; Hollevoet et al, 2011, 2012; Mori et al, 2013; Hassan et al,
2014). The earliest by Tajima et al (2008) included 14 patients with
MPM receiving a variety of chemotherapeutic regimens and tested
MPF and OPN prior to and following treatment. Despite small
numbers, the ratio between levels before and after therapy was
lower in those who had progressed on RECIST criteria (i.e., levels
Table 1. ( Continued )
Author (year) Study type Biomarker No. pts Histology Treatment
Thylen et al (1999) Prospective HA (s) 19 E – 15
S – 1
B – 3
N/D
Schouwink et al (1999) Retrospective TPA (s)
Ca125 (s)
CEA (s)
Cyfra21-1 (s)
52 E-31
S – 9
B – 10
Un – 2
C – 29
RTX – 5
Surg – 4
BSC – 14
Nakano et al (1998) Prospective IL-6 (s) 25 N/D N/D
Bonfrer et al (1997) Prospective TPA (s)
Cyfra21-1 (s)
29 E – 21
NE – 8
N/D
Dahl et al (1989) Prospective HA (s)
HA (pf)
37 E – 28
S – 3
B – 5
MC – 1
C – 37
Abbreviations: A¼Anaplastic; B¼biphasic; Bio¼biological therapy; BSC¼best supportive care; C¼ chemotherapy; CEA¼ carcinoembryonic antigen; CRP¼C reactive protein;
CTC¼ circulating tumour cells; D¼desmoplastic; E¼ epithelioid; HA¼ hyaluronic acid; HMGB1¼ high-mobility group box 1; Im¼ immunotherapy; IL¼ interleukin; MC¼multicystic;
MPF¼megakaryocyte potentiating factor; N/D¼not documented; NE¼non-epithelioid; OPN¼osteopontin; p¼plasma; pf¼pleural fluid; PDGF= platelet derived growth factor;
RTX¼ radiotherapy; S¼ sarcomatoid; s¼ serum; SM¼ soluble mesothelin; Surg¼ surgery; TPA¼ tissue polypeptide antigen; U¼ unknown; VEGF¼ vascular endothelial growth factor.
Table 2. Studies assessing treatment response or survival using serial serum SM during treatment
Author (year) Treatment (no. of patients) Outcome measure Threshold for SM change Results
Hooper et al (2015) P/C – 58, BSC – 15 Mod RECIST CT
OS, TTP
0% Chemotherapy group; a falling serum SM at
6–8 weeks was associated with longer time
to progression (Po0.001), and a falling SM
post chemotherapy was associated with
improved OS (P¼ 0.031)
Hassan et al (2014) P/C and Im – 20 Mod RECIST CT 15% Fall in serum SM correlated with radiological
response with 70% accuracy (P¼0.003)
Nowak et al (2013) Bio – 53 Mod RECIST CT
FDG-PET
OS, TTP
0% Median change in serum SM correlated with
sum change in tumour bulk on FDG-PET
(Po0.05). % change in serum SM was
associated with TTP (Po0.001) but not OS
Franko et al (2012) G/C – 56, P/C – 8, BSC – 4,
Surg – 10
Mod RECIST CT n/a Significantly lower mean serum SM in partial
response or stable disease compared to
progressive disease (P¼0.001)
Hollevoet et al (2011) P/C – 57, Surg – 5 Mod RECIST CT 15% Partial response to chemotherapy
correlated with a 34% fall in SM (P¼0.010)
compared with a 54% rise in progressive
disease (Po0.001)
Creaney et al (2011) Chemo – 61, BSC – 25, Surg – 8 Mod RECIST CT
FDG-PET
OS
25% Chemotherapy group; correlation between
change in serum SM and CT (P¼ 0.023) and
FDG-PET (Po0.001) Also, a falling SM was
associated with better OS (19 months)
compared with static (13 months) or rising
levels (15 months). (P¼ 0.001)
Wheatley-Price et al
(2010)
Chemo – 21, BSC – 13, Surg – 8 Mod RECIST CT
RECIST CT
CT report
10% or 5 nmol l1 Chemotherapy and BSC groups; relative
change in serum SM from baseline
significantly associated with disease
progression (Po0.010)
Grigoriu et al (2009) Chemo – 20, Im – 16, BSC – 4 Mod RECIST CT 10% In patients with raised SM at baseline
(41nM l1), rising level correlated with
progressive disease in 12 out of 16 patients.
OS higher in patients with stable SM
compared with increasing (P¼0.012)
Abbreviations: Bio¼biological therapy; BSC¼best supportive care; C¼ cisplatin; Chemo¼ chemotherapy (not specified); G¼gemcitabine; Im¼ immunotherapy; Mod RECIST CT¼modified
response evaluation criteria in solid tumors CT; OS¼overall survival; P¼pemetrexed; Surg¼ surgery; TTP¼ time to progression.
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had risen) compared with those with a partial response (Po0.05).
A larger study was performed by Hollevoet et al (2011) on 62
patients receiving either extrapleural pneumonectomy (n¼ 14) or
pemetrexed/platinum-based chemotherapy (n¼ 48). Patients had
modified RECIST CTs and matched MPF, SM and OPN levels (no
greater than 3 weeks apart) before and after treatment. In the
surgical group, only five patients had pre- and post-treatment
samples and median levels of both MPF and SM fell by 76% and
78%, respectively (median OPN levels actually rose by 20%). In the
chemotherapy group, the authors classified a change in biomarker
level as a change of415% from baseline. They demonstrated that
serum MPF (and SM) could predict treatment response, with a
median 53% fall in partial response (n¼ 14) compared with 58%
rise in progressive disease (n¼ 16). This study did not show any
correlation between baseline MPF and OS. However, a study from
the same author investigated the effect of age, BMI and renal
function on serum MPF and SM levels, finding that only renal
function altered biomarker levels in 106 MPM patients
(a worsening renal function increased serum MPF and SM)
(Hollevoet et al, 2012). Once this and other covariates were
considered, baseline serum MPF (and not SM) was found to
correlate with OS (P¼ 0.040). Finally, in a Phase 1 dose escalation
study of an anti-mesothelin immunotherapy called SS1P (in
combination with Pemetrexed and Cisplatin), the serum biomar-
kers MPF, SM and Ca125 were tested for correlation with
treatment response (mod RECIST CT) (Hassan et al, 2014).
Twenty patients were evaluable with biomarkers pre and post
treatment. All three biomarkers showed ‘strong significant
correlation’ with partial response, stable disease or progressive
disease. The biomarkers’ accuracy in predicting response on
CT was assessed with 15% used as a cut-off for change in
biomarker levels from baseline. Megakaryocyte potentiating
factor correctly classified 15 out of 20 patients (75% accuracy) as
having progressive or stable disease (with rising or stable/
falling levels, respectively) based on their CT scan, compared with
14 out of 20 (70%) and 12 out of 20 (60%) for SM and Ca125,
respectively.
Osteopontin (OPN). All six of the studies (six prospective) that
assessed serum/plasma OPN, with a total of 498 patients, were
looking at its role alongside other biomarkers. Two of these studies,
total of 185 patients, also examined pf OPN (Grigoriu et al, 2007;
Tajima et al, 2008; Wheatley-Price et al, 2010; Hollevoet et al, 2011;
Abakay et al, 2014; Mundt et al, 2014a; Pass et al, 2016). Grigoriu
et al (2007) measured baseline serum and pf OPN and SM (SM
results above) in a cohort of 96 MPM patients. Baseline serum
OPN had a statistically significant relationship with OS at
multivariate analysis in a model that included tumour histology
(HR: 3.46, CI: 1.1–10.9, P¼ 0.034). Using a cut-off of 350 ngml 1
(selected using a maximisation of HR model), patients with a low-
serum OPN had a median OS of 15 months compared with 5
months in high-serum OPN levels. Pleural fluid OPN was also
measured and was not found to correlate with OS. Serum OPN’s
ability to act as a baseline prognostic marker was replicated by
Hollevoet et al (2011) (study discussed above). Baseline OPN
correlated with both OS and PFS (optimum cut-off for their data
set was 863 ngml 1) and appeared to be an independent factor
with no correlation with other biomarkers or tumour stage. More
recently, Pass et al investigated the benefit of adding baseline
plasma biomarker levels to previously validated prognostic tools
(EORTC prognostic index of mesothelioma and the CALGB
index). In a discovery cohort of 83 patients, of whom two-thirds
had cytoreductive surgery, baseline levels of plasma OPN, SM and
fibulin-3 were measured. Both the plasma OPN and SM, but not
fibulin-3, were independently correlated with OS. Interestingly, in
a prognostic model including well known poor prognostic
indicators such as low Hb and EORTC score (41.27) only high
OPN remained an independently significant predictor of worse
prognosis.
A study by Mundt et al (2014a) analysed serum and pf OPN
from two separate cohorts to assess its role in diagnosis and
prognosis at baseline. Although the diagnostic analysis of serum
OPN involved 91 patients with MPM, full survival analysis was
only available for 19 patients. Despite this data attrition, serum
OPN was found to correlate with OS using a 185 ngml 1 cut-off
(HR: 2.5, CI: 1.4–10.3), the median of the data set. In the pf cohort,
40 patients had survival data available and using pf OPN cut-off of
1.6 mgml 1 resulted in median OS times of 29m vs 13m for low to
high levels, respectively (HR: 2.2, CI: 1.2–4.2). However, neither of
these correlations were assessed using multivariate analysis or
evaluated alongside tumour histology.
Fibulin-3. Six studies (five prospective, one retrospective) invol-
ving serum/plasma fibulin-3 were found by this systematic review,
comprising 568 patients overall (Pass et al, 2012; Creaney et al,
2014; Hooper et al, 2015; Kaya et al, 2015; Kirschner et al, 2015;
Pass et al, 2016). Of these, three studies (two prospective, one
retrospective), with a total of 186 patients, also measured pf fibulin.
No study found serum/plasma fibulin-3 to be a significant marker
of prognostication at baseline. Hooper et al (2015) measured serum
fibulin-3 before, during (after two cycles of Pem/Cis) and after
chemotherapy. Baseline levels were higher in the epithelioid
subtypes but there was no correlation with OS when histological
subtypes were analysed separately. In addition, serial sampling did
not predict treatment response or PFS.
The earliest study to analyse pf fibulin-3 as a prognostic marker was
carried out by Pass et al (2012). The primary outcome was fibulin-3’s
diagnostic utility, so survival data was only available for a proportion of
the pf cohort (n¼ 54). PF fibulin-3 correlated with pathological stage,
with stages 1 and 2 (n¼ 21) having a median level of 576ngml 1
compared with 765ngml 1 in stages 3 and 4 (P¼ 0.040). When pf
fibulin-3 levels were dichotomised at the database median of
733.4ngml 1 a low baseline level inferred better OS and this
remained significant in a multivariate model that included gender,
stage and histological subtype (P¼ 0.024). Creaney et al (2014) also
measured both serum and pf fibulin-3 in a prospectively collected
cohort of 82 patients with MPM with a focus on diagnostic utility but
with follow-up data for the majority of the cohort (n¼ 78). Patients
with biphasic or sarcomatoid histology had significantly (P¼ 0.002)
higher pf fibulin-3 concentrations (median 1331ngml 1) compared
with epithelioid subtypes (median 426ngml 1), but no relationship to
tumour stage. A linear negative relation was found between OS and pf
fibulin-3 and remained significant at multivariate analysis (P¼ 0.017).
Lastly, a retrospective analysis of three cohorts of MPM patients
(serum n¼ 37 and n¼ 47, pf n¼ 30) found that lower pf fibulin-3, but
not serum, was associated with improved OS at multivariate analysis
(Kirschner et al, 2015).
Hyaluronic acid (HA). Four studies (two prospective, two
retrospective), with a total of 163 patients, assessed the utility of
serum HA between 1989 and 2013 (Dahl et al, 1989; Thylen et al,
1999; Hedman et al, 2003; Creaney et al, 2013). Pleural fluid HA
was measured in three of the selected studies (one prospective, two
retrospective), with a total of 233 patients (Dahl et al, 1989; Thylen
et al, 2001; Creaney et al, 2013). The earliest study, from Dahl
et al (1989), measured serial serum HA in patients undergoing
methotrexate therapy for pleural (n¼ 34) or peritoneal (n¼ 3)
mesothelioma. They showed that serum HA were higher
in later disease stage but presented no data regarding histological
subtypes. Additionally, in patients who were deemed to have
progressed, based on subjective CT reporting (n¼ 13), levels of
HA rose (median¼ 25, IQR 6–37) compared with falling levels
in responders (n¼ 20) (median¼  5, IQR:  14–3). Pleural
fluid HA did not correlate with serum levels and there was no
relationship between tumour stage or disease response. In contrast,
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a more recent case series retrospectively analysed serum and pf HA
in 96 MPM cases (Creaney et al, 2013). In this study, serum HA
was not significantly raised in MPM patients compared with
patients with benign conditions or lung cancer with no relationship
with OS. Pleural fluid HA was significantly higher in MPM
patients and demonstrated a biphasic distribution that was
independent of tumour histology. Although no treatment data
was presented, using a cut-off of 75mgml 1, there was a survival
benefit for high pf HA levels (18 months) compared with low levels
(12.6 months). The phenomena of high pf HA and improved
survival is replicated by Thylen et al (2001) who measured pf levels
in patients receiving either chemotherapy (n¼ 56) or BSC (n¼ 44),
although histological subtypes were not analysed separately.
Vascular endothelial growth factor (VEGF). This systematic
review identified six papers involving serum/plasma (four
prospective, one retrospective) or pf (one retrospective, one
prospective) vascular endothelial growth factor (VEGF) levels,
with a total of 287 and 53 patients, respectively, (Strizzi et al,
2001; Yasumitsu et al, 2010; Hirayama et al, 2011; Kao et al, 2012;
Kindler et al, 2012; Nowak et al, 2013). A 7-year prospective
single centre case series of 51 patients with MPM analysed serum
pan-VEGF levels and compared them to a non-MPM asbestos-
exposed population (n¼ 42) (Yasumitsu et al, 2010). Serum
VEGF levels were significantly higher in the MPM population
and increased with tumour stage. Median levels were higher
in epithelioid vs sarcomatoid histology (1071 pgml 1 vs
580 pgml 1, respectively) but because of low numbers of
sarcomatoid cases (n¼ 6), this result was not statistically
significant. At multivariate analysis, there was no significant
correlation with OS. Kao et al (2012) analysed a variety of novel
biomarkers (pan-VEGF, CRP, IL-6, sIL-6R and SM) in a non-
randomised trial of thalidomide as a chemotherapy adjunct
(n¼ 34) or single agent (n¼ 29). At multivariate analysis,
baseline serum VEGF was the only significant biomarker in
predicting OS (P¼ 0.025), with higher median survival in lower
VEGF levels. In addition, VEGF levels were tested post
chemotherapy (at 8 weeks). Patients with high baseline levels
that subsequently fell had median OS of 79 weeks compared with
39 weeks (P¼ 0.050).
A phase II trial of second-line therapy (Sunitinib Malate, a
multitargeted tyrosine kinase inhibitor) robustly assessed the role
of several serum VEGF isoforms in prognostication (Nowak et al,
2013). Fifty-three patients with progression following conventional
chemotherapy were enroled, with only one patient with sarcoma-
toid MPM meeting eligibility criteria. Several serum VEGF
isoforms were tested (A, C, R2 and R3) as well as SM, c-kit and
IL-8 at baseline, 6 weeks and every 12 weeks thereafter. Baseline
VEGF-A and VEGF-R2 were predictive of radiological response at
multivariate analysis, with only percentage change in SM being
associated with time to progression (HR: 3.84, Po0.001). Another
trial of biological therapy compared bevacizumab (a monoclonal
antibody to VEGF) to placebo when added to chemotherapy with
gemcitabine and cisplatin in 108 patients with MPM (Kindler et al,
2012). Vascular endothelial growth factor levels were measured
pre-treatment in 56 patients. The trial found no difference between
the two treatment arms with partial response rates of 24.5% and
21.8% for the bevacizumab and placebo arms, respectively,
(P¼ 0.74). There was no significant difference in baseline VEGF
levels between responders and non-responders, although higher
baseline levels were associated with worse PFS (P¼ 0.049) and OS
(P¼ 0.014).
A diagnostic study measured pf pan-VEGF levels in 46 MPM
patients (Hirayama et al, 2011). In the 28 patients followed up to
600 days, those with a pf VEGF 42000 pgml 1 (a pre-defined
cut-off) had lower OS at multivariate analysis (HR; 961.2, CI: 7.1–
130 446, P¼ 0.006).
DISCUSSION
This systematic review identified 45 studies from the current
literature that assessed the prognostic or treatment monitoring
ability of biomarkers in MPM. There was significant variation in
the quality of the selected studies with many having a moderate to
high risk of bias due to study attrition or lack of reporting of
confounding factors (as evidenced by the variation in QUIPS
scores). In addition, there was considerable heterogeneity within
studies regarding patient treatment (variation in numbers under-
going standard chemotherapy, trial drugs, surgery or BSC), which
is a major confounder in prognostic studies that can only be partly
adjusted for using multivariate analysis. Several papers combined
these groups when assessing a biomarker’s baseline prognostic
ability, making many of their conclusions invalid.
Robust methodology was used to capture all available literature,
including an evidence-based search strategy, multiple independent
reviewers, PRISMA reporting methodology and the use of the
QUIPS tool for study assessment. However, given the inter-study
variability in biomarker cut-offs, histological subtypes, treatment
modalities and outcome measures (OS, PFS or radiological
treatment response) no attempt to meta-analyse the studies was
made.
The majority of selected studies examined the utility of serum
SM as a baseline prognostic indictor, often as a secondary outcome
to its diagnostic utility. Earlier case series suggested higher baseline
levels inferred a worse prognosis, but this finding was inconsis-
tently replicated by more recent studies. Soluble mesothelin is only
expressed by tumours with full or partial epithelioid histology, so
variation between studies in histological subtypes has a significant
impact on the interpretation of these results. Several studies have
demonstrated no correlation with OS when tumour histology and
renal function (renal function is inversely correlated with serum
SM) are included in multivariate analyses. When serum SM is
measured serially it has been consistently shown to correlate with
changes in modified RECIST CT findings or survival (OS and
PFS). The eight studies examining this relationship focused on
patients receiving chemotherapy, with only 34 patients having had
surgery. Between studies, there was variation in the thresholds used
to define a significant change in serum SM as well as the
appropriate sampling intervals during or after treatment. Before
serial SM testing can be recommended in routine clinical practice a
large prospective study is required to address these uncertainties
and assess its use in surgical and BSC cohorts. Megakaryocyte
potentiating factor is formed from the same precursor protein as
SM and is a more novel biomarker in MPM (Hollevoet et al, 2010).
Megakaryocyte potentiating factor and SM correlated strongly in
the three studies that measured both concurrently but the strength
of evidence for serum MPF is far smaller than for SM.
This systematic review identified several studies that correlated
high OPN levels with poor prognosis, including within prognostic
tools. Also plasma OPN showed no correlation with other
biomarkers, indicating that it may offer independent prognostic
information. There was significant variability in the cut-offs used
between studies, which is likely reflective of the variation in
treatment modality between cohorts as well as the ELISA platforms
used (Anborgh et al, 2009). In addition, because OPN is cleaved by
thrombin following blood coagulation, plasma sampling is superior
to serum (Pass et al, 2016). The majority of studies found by this
review analysed plasma OPN, but in order for this biomarker to be
validated in the future a consensus approach is required for
sampling and analysis.
Serum fibulin-3 has shown promise as a diagnostic biomarker
(Pass et al, 2012) but was not a marker of prognosis on the basis of
this systematic review. However, higher levels of fibulin-3 in pf did
inversely correlate with survival, although this is likely in part due
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to the much higher levels found in effusions of the more aggressive
sarcomatoid MPM.
Vascular endothelial growth factor is a well-documented marker
of tumour angiogenesis and is raised in the serum of patients with
MPM (Strizzi et al, 2001). It is of particular importance in MPM
given the emergence of antiangiogenic VEGF-targeted treatments
that have been shown to improve survival when given in
combination with pemetrexed and cisplatin (Zalcman et al,
2016). The studies involving serum VEGF were heterogeneous in
terms of design but showed positive results for pan-VEGF and its
isoforms as prognostic or monitoring biomarkers. No studies
demonstrated any ability of serum VEGF to select responders from
non-responders for biologic therapy, but this area demands further
study given the development of promising but expensive
biologicals (Kindler et al, 2012; Nowak et al, 2013).
In conclusion, from the 45 studies published in the literature no
serum or pf biomarker was identified that could be recommended
currently for use in clinical practice. There was considerable
heterogeneity within studies for patient treatment, tumour histo-
logy and follow-up, as well as inter-study variability in terms of
biomarker cut-offs. Serum SM when measured before and after
treatment has been shown to track treatment response but further
studies are required to ascertain its place in the chemotherapy or
surgical management pathway. Serum OPN showed an ability to
prognosticate from baseline, but whether this has clinical utility is
uncertain. With considerable variation in response rates to chemother-
apy and the emergence of promising biological therapies, biomarkers
that could select responders from non-responders at baseline or during
treatment would aid clinical decision making, prevent patients getting
ineffective therapy and improve cost effectiveness.
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